With over 16,000 attendees, BIO is one of the largest biotech partnering, education, and networking events in the world. Be sure to stop by VGXI’s Booth #3349 or schedule a meeting with one of our representatives during the conference to learn how VGXI’s plasmid manufacturing services can support your gene or cell therapy program! Contact Us directly or use BIO’s One-On-One… Read More »
VGXI to Exhibit at the 2019 BIO International Convention
VGXI Celebrates Grand Opening of New Flex-Scale Production Plant for GMP
U.S. Congressman Kevin Brady visited Texas-based CMO VGXI to celebrate the grand opening of the company’s new flexible scale GMP production plant for DNA and RNA based therapeutics. VGXI, an industry recognized plasmid DNA contract manufacturing organization, announced the grand opening of a facility expansion which includes flexible scale plasmid DNA manufacturing space as well… Read More »
Meet VGXI at the AAV Gene Therapy Symposium
Meet with representatives from VGXI at the 2nd Annual AAV Gene Therapy Symposium on 10 December, 2018. We would welcome an opportunity to introduce ourselves and share information on VGXI’s customized plasmid DNA manufacturing solutions to support your AAV production needs. Contact Us today to request a meeting. 2018 AAV Gene Therapy Symposium 10 December, 2018 Bioscience… Read More »
Meet VGXI at the 2018 ASGCT Annual Meeting
Will you be attending the ASGCT 21st Annual Meeting in May, 2018? Meet with representatives from VGXI at Booth # 105 and learn more about our products and services! We also welcome requests for partnering meetings during the conference. Contact Us today to make arrangements. ASGCT’s 21st Annual Meeting 16-19 May, 2018 Hilton Chicago
VGXI is a Finalist for BEST CMO at the 2018 ViE Awards!
As a leading GMP manufacturer of high quality plasmid DNA, VGXI, Inc. has been recognized in the final shortlist of companies for the category of “Best Contract Manufacturing Organization (CMO)” for the 2018 Vaccine Industry Excellence Awards. Click here to view the full list of finalists for the ViE Awards Will you be attending the World Vaccine Congress in… Read More »
VGXI Breaks Ground on Facility Expansion
Texas based plasmid CMO VGXI breaks ground on facility expansion and new flex-scale GMP production plants. The Woodlands, TX – February 22, 2018 – VGXI announced today they have broken ground on a 5,000 square foot expansion of their Texas based manufacturing facility. Once complete, the project will increase the company’s footprint by 17% and… Read More »
Submit Your Nominations for the 2018 ViE Awards
Nominations are now open for the Vaccine Industry Excellence Awards of the 2018 World Vaccine Congress this April! Show your support for VGXI, Inc. by nominating us for the categories of “Best CMO” and “Best Production/Process Development“. Submit your nominations at the following link by 12Jan18: http://www.terrapinn.com/conference/world-vaccine-congress-washington/2018-ViE-Awards-Categories.stm
Meet VGXI at the 2017 ISV Congress
Heading to Paris in October? Meet with representatives from VGXI and learn more about our products and services! We also welcome requests for partnering meetings during the conference. Contact Us today to make arrangements. 2017 International Society of Vaccines Annual Congress October 5 – 7, 2017 Institute Pasteur Paris, France
View our poster presented at the ASGTC 2017 Annual Meeting
Did you miss us at ASGCT? Download our poster at the link below: Novel Method for RNA Quantification and Exclusion from Plasmid DNA Vector Purification Process Stream Presented on Thursday, May 11, 2017 from 5:15 pm – 7:15 pm Session Information: Vector and Cell Engineering and Manufacturing Location: Exhibit Hall C & B South Abstract #484… Read More »
VGXI Wins 2017 Vaccine Industry Excellence (ViE) Award for Best Contract Manufacturing Organization
VGXI announced that on April 10th, 2017 the corporation won the award for Best Production / Process Development at the 10th Annual ViE Awards Ceremony held at the 2017 World Vaccine Congress in Washington, D.C.
IVI, GeneOne Life Science join forces to develop MERS-CoV vaccine
IVI and GeneOne Life Science to collaborate in clinical development of GeneOne’s DNA-based MERS-CoV vaccine. The collaboration will accelerate vaccine development and ensure access for public health readiness in case of future outbreaks in Korea and worldwide. Signing ceremony for MERs-CoV vaccine development collaboration. The International Vaccine Institute (IVI) and GeneOne Life Science Inc. have… Read More »
VGXI Hosts Biotech Roundtable Discussion with U.S. Congressman Pete Olson
On November 18, 2016 VGXI hosted a roundtable discussion with US Congressman Pete Olson and key biotech industry leaders. From left: U.S. Congressman Pete Olson; Ann Tanabe, CEO of BioHouston; Young Park, CEO of GeneOne Life Science; Jim Greenwood, President of BIO; Dorothy Peterson, VP of Operations at VGXI; and Tom Kowalski, President and CEO… Read More »